BioSpace News Archive

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.

Eirion Therapeutics Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial for the treatment of glabellar wrinkles using the next generation, ready-to-use liquid injectable neuromodulator AI-09.

Lyfebulb and Veloxis Pharmaceuticals are excited to announce that Biohope was selected as the winner of the Innovation Award and C. Alan Foundation as the winner of the Impact Award at the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation.

Located in the West of Scotland Science Park, this new facility will produce fresh leukopaks for cell and gene therapy research in the UK and Europe

Indiana-based radiopharmaceutical developer and manufacturer completes FDA inspection on behalf of the European Medicines Agency (EMA)

Exacis Biotherapeutics Inc. (“Exacis” or the “Company”) today announced that it has signed an option agreement with Eterna Therapeutics Inc. (“Eterna”) providing Eterna the right to license up to four off-the-shelf, iPSC derived NK cell and T cell cancer treatments to be produced using Exacis’ proprietary mRNA-reprogrammed iPSCs that will be engineered with Exacis’ mRNA-based gene editing platform.

According to Nova one advisor, the global Active Pharmaceutical Ingredient market size is expected to hit around USD 354.1 billion by 2030 from valued at USD 209.9 billion in 2021 and growing at a CAGR of 7.2% from 2022 to 2030.

According to the global CRISPR And Cas Genes market size is expected to surpass around USD 9.85 billion by 2030 from valued at USD 2.09 billion in 2021 and growing at a CAGR of 17.60% from 2022 to 2030.

According to the global Genome Editing market size is expected to surpass around USD 25.4 billion by 2030 from valued at USD 4.7 billion in 2021 and growing at a CAGR of 28.4% from 2022 to 2030.